Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GNX102 |
Synonyms | |
Therapy Description |
GNX102 is a monoclonal antibody targeting the Lewis B and Lewis Y glycans, which may lead to antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing these glycans (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GNX102 | GNX-102|GNX 102 | GNX102 is a monoclonal antibody targeting the Lewis B and Lewis Y glycans, which may lead to antibody-dependent cellular cytotoxicity (ADCC) against tumor cells expressing these glycans (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04250597 | Phase I | GNX102 | Study of GNX102 in Patients With Advanced Solid Tumors | Terminated | USA | 1 |